Phase 2 study of SAB-301 in patients with Middle-East-respiratory-syndrome-coronavirus

Trial Profile

Phase 2 study of SAB-301 in patients with Middle-East-respiratory-syndrome-coronavirus

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs MERS monoclonal antibody (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2016 New trial record
    • 24 Aug 2016 According to SAB Biotherapeutics media release, this trial is conducted by the National Institutes of Health (NIH).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top